Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Benjamin J SolomonTony S Mok

Abstract

Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK) -positive advanced nonsquamous non-small-cell lung cancer. Here, we report the final overall survival (OS) results. Patients and Methods Patients were randomly assigned to receive oral crizotinib 250 mg twice daily (n = 172) or intravenous pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 or carboplatin (area under the concentration-time curve of 5 to 6 mg·mL/min) every 3 weeks for a maximum of six cycles (n = 171). Crossover to crizotinib was permitted after disease progression. OS was analyzed using a stratified log-rank test and a prespecified rank-preserving structural failure time model to account for crossover. Results Median follow-up duration for OS was approximately 46 months for both arms. In the chemotherapy arm, 144 patients (84.2%) received crizotinib in subsequent lines. Hazard ratio for OS was 0.760 (95% CI, 0.548 to 1.053; two-sided P = .0978). Median OS was not reached (NR) with crizotinib (95% CI, 45.8 months to NR) and 47.5 months with chemotherapy (95% CI, 32.2 months to NR). Survival probability at 4 years was 56.6% (95% CI, 48.3% to 64.1%) with crizotinib and 4...Continue Reading

References

Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
May 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio Vittorio ScagliottiDavid Gandara
Aug 13, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Scott J RodigLucian R Chirieac
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
May 23, 2014·JAMA : the Journal of the American Medical Association·Mark G KrisPaul A Bunn
Dec 4, 2014·The New England Journal of Medicine·Benjamin J SolomonUNKNOWN PROFILE 1014 Investigators
Mar 1, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Justin F GainorAlice T Shaw
Sep 24, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Rita ChiariLucio Crinò
Aug 9, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kentaro ItoNobuyuki Yamamoto
Jun 7, 2017·The New England Journal of Medicine·Solange PetersUNKNOWN ALEX Trial Investigators

❮ Previous
Next ❯

Citations

Sep 29, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D B Costa
Nov 6, 2018·Current Opinion in Oncology·Christoph Oliver RyserOliver Gautschi
Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Alberto PucciniFrancesca Battaglin
Apr 23, 2019·Japanese Journal of Clinical Oncology·Naomi UenoAkihiko Gemma
May 8, 2019·Cardiovascular and Interventional Radiology·Pernelle LavaudLambros Tselikas
May 18, 2019·American Society of Clinical Oncology Educational Book·Jordi Rodon AhnertJustin Gainor
Apr 14, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A T ShawS-H I Ou
Jul 23, 2019·Expert Opinion on Pharmacotherapy·G Hamilton, M J Hochmair
Sep 5, 2019·Current Treatment Options in Oncology·Alex FriedlaenderAlfredo Addeo
Dec 17, 2019·Respirology : Official Journal of the Asian Pacific Society of Respirology·Mei-Kim Ang, Tony S K Mok
Dec 7, 2019·Expert Review of Anticancer Therapy·Collin M Blakely, Jonathan W Riess
Jan 10, 2020·Expert Review of Respiratory Medicine·Carlo GenovaFrancesco Grossi
Jan 22, 2020·Journal of Comparative Effectiveness Research·Meijuan HuangYou Lu
Aug 20, 2019·ESMO Open·Michael G McCuskerChristian Rolfo
May 30, 2019·Oncotarget·Petros ChristopoulosAlbrecht Stenzinger
Nov 15, 2018·ESMO Open·Jordi Remon, Rodrigo Dienstmann
Apr 1, 2020·Expert Review of Anticancer Therapy·Andrea Sartore-BianchiSalvatore Siena
Jul 21, 2020·Clinical Pharmacology and Therapeutics·Stefanie L GroenlandNeeltje Steeghs
Aug 16, 2018·Nature Reviews. Clinical Oncology·Gonzalo RecondoLuc Friboulet
Jan 20, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·J RemonS Novello
Nov 8, 2018·International Journal of Molecular Sciences·Hao Huang
Mar 21, 2019·Expert Review of Respiratory Medicine·Jose M Pacheco, David R Camidge
Jan 29, 2019·Frontiers in Oncology·Muhammad KhanYawei Yuan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The New England Journal of Medicine
Benjamin J SolomonPROFILE 1014 Investigators
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Benjamin J SolomonTony S K Mok
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Giorgio ScagliottiNasser Hanna
© 2022 Meta ULC. All rights reserved